Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.